SCHEMBL1481318

SCHEMBL1481318

O=C(O)CCCOc1ccc(-c2ccc(C=Cc3nc(-c4ccc(Cl)cc4Cl)cn3CC(=O)NCc3ccc(OC(F)(F)F)cc3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 7/20 0.43
FFAR1 O14842 4/20 0.43
SCN5A Q14524 2/20 0.43
CYP2C9 P11712 1/20 0.43
CNR1 P21554 6/20 0.40
GCGR P47871 2/20 0.39
CYP3A4 P08684 1/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA1C Q13936 1/20 0.38
MEN1 O00255 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
CYSLTR2 Q9NS75 1/20 0.37
CYSLTR1 Q9Y271 1/20 0.37
ALDH1A1 P00352 1/20 0.36
RIPK1 Q13546 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481314 1.00 FFAR4 (0.43) FFAR4FFAR1SCN5ACYP2C9CNR1
SCHEMBL1482891 0.93 CNR1 (0.42) FFAR4FFAR1SCN5ACYP2C9CNR1
SCHEMBL1481637 0.93 CNR1 (0.42) FFAR4FFAR1SCN5ACYP2C9CNR1
SCHEMBL1481966 0.93 CNR1 (0.47) CNR1MEN1RECQLKMT2ACYSLTR2
SCHEMBL1483140 0.93 CNR1 (0.47) CNR1MEN1RECQLKMT2ACYSLTR2
SCHEMBL1480567 0.91 CNR1 (0.51) FFAR1CNR1GCGRCYP3A4MEN1
SCHEMBL1480569 0.91 CNR1 (0.51) FFAR1CNR1GCGRCYP3A4MEN1
SCHEMBL1481421 0.90 FFAR4 (0.48) FFAR4FFAR1SCN5ACYP2C9GCGR
SCHEMBL1481418 0.90 FFAR4 (0.48) FFAR4FFAR1SCN5ACYP2C9GCGR
SCHEMBL1481827 0.90 CNR1 (0.44) CYP2C9CNR1GCGRCYP3A4RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ FFAR4 2604/4885FFAR1 1810/4885SCN5A 779/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ FFAR4 2604/4885FFAR1 1810/4885SCN5A 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.